EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Christine M Bestvina, Jared H L Hara, Theodore Karrison, Benjamen Bowar, Janet Chin, Marina C Garassino, Sean P Pitroda, Rajat Thawani, Everett E Vokes, Gregory Gan, Jun Zhang, Andrew M Baschnagel und 3 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Christine M Bestvina und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Hematology and Oncology, The University of Chicago Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms, Radiosurgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immunotherapy in combination with chemotherapy is first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). Growing evidence suggests that radiation, specifically stereotactic body radiation therapy (SBRT), may enhance the immunogenic response as well as cytoreduce tumor burden. The primary objective of the study is to determine the progression free survival for patients with newly diagnosed ES-SCLC treated with combination multisite SBRT and chemo-immunotherapy (carboplatin, etoposide, and durvalumab). METHODS: This is a multicenter, single arm, phase 2 study. Patients with treatment-naïve, ES-SCLC will be eligible for this study. Patients will receive durvalumab 1500mg IV q3w, carboplatin AUC 5 to 6 mg/mL q3w, and etoposide 80 to 100 mg/m2 on days 1 to 3 q3w for four cycles, followed by durvalumab 1500mg IV q4w until disease progression or unacceptable toxicity. Ablative radiation will be delivered 1 to 4 extracranial sites in 3 or 5 fractions, determined by location, during cycle 2. The primary endpoint is progression-free survival, measured from day 1 of chemoimmunotherapy. Secondary endpoints include grade ≥3 toxicity by CTCAE v5.0 within three months of RT, overall survival, response rate, time to second line systemic therapy, and time to new distant progression. CONCLUSIONS: Now that immunotherapy is an established part of ES-SCLC management, it is important to further optimize its use and effect. This study will investigate the progression-free survival of combined SBRT and chemo-immunotherapy in patients with ES-SCLC. In addition, the data from this study may further inform the immunogenic role of SBRT with chemo-immunotherapy, as well as identify clinical, biological, or radiomic prognostic features.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsRadiosurgerySmall Cell Lung CarcinomaFemaleHumansMaleCarboplatinCombined Modality TherapyEtoposideImmunotherapyNeoplasm StagingSurvival RateMulticenter Studies as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

ChemoimmunotherapyDurvalumabExtensive stage small cell lung cancerImmunotherapyStereotactic Body Radiation Therapy

Substanzen

Antibodies, MonoclonalCarboplatindurvalumabEtoposide

Autor:innen und Institutionen

  • Department of Medicine, Section of Hematology and Oncology, The University of Chicago Medicine, Chicago, IL.
  • Department of Radiation Oncology, The Queen's Medical Center, Honolulu, HI.
  • Department of Public Health Sciences, The University of Chicago, Chicago, IL.
  • Department of Pharmacy, University of Chicago Medical Center, Chicago, IL.
  • Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, IL.
  • Department of Radiation Oncology, Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS.

Förderung

  • AstraZeneca

Zitieren

APA

Bestvina, C. M., Hara, J. H. L., Karrison, T., Bowar, B., Chin, J., Garassino, M. C., Pitroda, S. P., Thawani, R., Vokes, E. E., Gan, G., Zhang, J., Baschnagel, A. M., Campbell, T. C., Chmura, S., & Juloori, A. (2024). DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.08.004

Vancouver

Bestvina CM, Hara JHL, Karrison T, Bowar B, Chin J, Garassino MC, et al. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.08.004

BibTeX
@article{Bestvina2024,
  author = {Bestvina, Christine M and Hara, Jared H L and Karrison, Theodore and Bowar, Benjamen and Chin, Janet and Garassino, Marina C and Pitroda, Sean P and Thawani, Rajat and Vokes, Everett E and Gan, Gregory and Zhang, Jun and Baschnagel, Andrew M and Campbell, Toby C and Chmura, Steven and Juloori, Aditya},
  title = {DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.08.004}
}
Kostenlos starten →